Urology and Uro-Oncology
In a single year, the number of Americans newly diagnosed with bladder cancer is estimated to be about 82,000.1
More than half of the patients diagnosed with high-risk non-muscle invasive bladder cancer (NMIBC) who receive initial treatment with the intravesical immunotherapy Bacillus Calmette-Guérin (BCG) will experience disease recurrence and progression within one year, with many developing BCG-unresponsive disease.2
Most patients need additional treatment options after BCG, but few options are available for adult patients with high-risk NMIBC following BCG treatment who have persistent or recurrent disease.3,4,5,
Ferring develops life-changing therapies to address the unmet medical needs of patients diagnosed with bladder and other urological cancers.
- American Cancer Society. Key statistics for bladder cancer. Accessed May 8, 2023. https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html
- Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021; 22:107–17.
- Di Lorenzo G, et al. Cancer 2010;116:1893–1900.
- Goossens-Laan CA, et al. Support Care Cancer 2014;22:189–200.
- Winters BR, et al. J Urol 2018;199:669–675.